Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

European Organisation For Research And Treatment Of Cancer
Sponsor

European Organisation For Research And Treatment Of Cancer

Belgium Emmanuel Mounierlaan 83 Bus 11, 1200 Woluwe-Saint-Lambert, Belgium

About the sponsor

Clinical research includes metastatic hormone-sensitive prostate cancer, castration-resistant prostate cancer, high-risk localized prostate cancer, and metastatic disease to bone, with interest in androgen deprivation therapy, anti-androgen agents, GnRH antagonists, and treatment strategies linked to PSA response and disease control.

  • Hormone therapy
  • Androgen receptor pathway inhibition
  • Bone-metastatic disease

Research also extends to symptom management during endocrine treatment and combinations with radiotherapy or radiopharmaceuticals.

About Specializations

European Organisation For Research And Treatment Of Cancer runs clinical trials in conditions such as Hormone-dependent prostate cancer, Squamous cell carcinoma of head and neck, Hormone receptor positive HER2 negative breast cancer, Astrocytoma malignant, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

23 clinical trials

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Meningioma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Uveal melanoma

Recruiting

Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Squamous cell carcinoma of head and neck

Recruiting

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Glioblastoma

Recruiting

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Leiomyosarcoma+1

Recruiting

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study on Improving Quality of Life for Early Breast Cancer Patients Using Duloxetine and Furosemide to Manage Endocrine Therapy-Related Pain

Registered drugNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Duloxetine
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Prostate cancer

Not recruiting

Study Comparing Degarelix and Drug Combination with Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Thymoma malignant

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.